

# The Role of Liquid Biopsies in Cancer Diagnosis: A Clinical Biochemistry Perspective

Roman Fiore\*

Department of medical oncology,  
University of Rouen, France

**Received:** 01-Nov-2023, Manuscript No. IPACLR-23-14287; **Editor assigned:** 02-Nov-2023, PreQC No. IPACLR-23-14287(PQ); **Reviewed:** 16-Nov-2023, QC No. IPACLR-23-14287; **Revised:** 21-Nov-2023, Manuscript No. IPACLR-23-14287(R); **Published:** 27-Nov-2023, DOI: 10.36648/2386-5180.23.11.491

\*Corresponding author:

Roman Fiore

## Introduction

Cancer, one of the leading causes of death worldwide, has long been a challenge for healthcare professionals. Traditional methods of cancer diagnosis often involve invasive procedures like tissue biopsies, which can be uncomfortable and carry certain risks [1,2]. However, recent advancements in clinical biochemistry have paved the way for a revolutionary approach: liquid biopsies. These non-invasive tests offer valuable insights into cancer detection, prognosis, and treatment monitoring, transforming the landscape of cancer diagnosis. This article explores the role of liquid biopsies in cancer diagnosis from a clinical biochemistry perspective [3].

**Understanding Liquid Biopsies:** Liquid biopsies involve the analysis of various biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, present in bodily fluids like blood. These biomarkers carry genetic information about the tumor and can be detected and analyzed through advanced molecular techniques. Unlike traditional biopsies, liquid biopsies offer a less invasive and more accessible method of capturing vital information about the cancer's genetic makeup [4,5].

**Early Detection and Prognosis:** One of the significant advantages of liquid biopsies is their ability to detect cancer at an early stage. ctDNA, released by tumor cells into the bloodstream, carries genetic mutations specific to the cancerous growth. By analyzing ctDNA, clinicians can identify these mutations even before the physical symptoms manifest, enabling early intervention and improved outcomes [6].

**Personalized Treatment Approaches:** Liquid biopsies play a crucial role in advancing the field of personalized medicine. By analyzing the genetic mutations and alterations detected in ctDNA, clinicians can identify targeted therapies tailored to the patient's unique genetic profile. This precision medicine approach maximizes the effectiveness of treatments while minimizing side effects, leading to better patient outcomes and enhanced quality of life [7].

**Monitoring Treatment Response:** In addition to diagnosis and prognosis, liquid biopsies are instrumental in monitoring a patient's response to treatment. Traditional imaging techniques might not capture subtle changes in tumor size or progression, especially during targeted therapies. Liquid biopsies, on the

other hand, provide a dynamic and real-time view of the cancer's genetic landscape. Monitoring ctDNA levels allows clinicians to assess the treatment's efficacy promptly. If the treatment proves ineffective, adjustments can be made swiftly, ensuring that patients receive the most suitable therapies throughout their cancer journey [8,9].

**Challenges and Future Directions:** While liquid biopsies hold immense promise, challenges such as standardization of testing methods, cost, and insurance coverage need to be addressed. Researchers and healthcare professionals are actively working to overcome these hurdles, aiming to make liquid biopsies a routine part of cancer diagnosis and management [10].

## Conclusion

Liquid biopsies represent a groundbreaking advancement in cancer diagnosis, offering a comprehensive and non-invasive approach to understanding the disease. From early detection to personalized treatment strategies and real-time monitoring, these tests have the potential to revolutionize cancer care. As clinical biochemistry continues to evolve, the integration of liquid biopsies into routine practice holds the key to improving cancer outcomes and providing hope to patients and their families facing this challenging diagnosis.

## References

1. De Rubis G, Krishnan SR, Bebawy M (2019). Liquid biopsies in cancer diagnosis, monitoring, and prognosis. *Trends Pharmacol. Sci.* 40(3):172-86.

2. Vaidyanathan R, Soon RH, Zhang P, Jiang K, Lim CT(2019) . Cancer diagnosis: from tumor to liquid biopsy and beyond. *Lab on a Chip.* 19(1):11-34.
3. Mader S, Pantel K (2017). Liquid biopsy: current status and future perspectives. *Oncol Res Treat.* 40(7-8):404-8.
4. Fernández-Lázaro D, García Hernández JL, García AC, Córdova Martínez A, Mielgo-Ayuso J, et al (2020). Liquid biopsy as novel tool in precision medicine: Origins, properties, identification and clinical perspective of cancer's biomarkers. *Diagnostics.* 10(4):215.
5. Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, et al (2014). Liquid biopsies in lung cancer: the new ambrosia of researchers. *Biochim Biophys Acta Rev Cancer.* 1846(2):539-46.
6. Alix-Panabières C, Pantel K (2013). Circulating tumor cells: liquid biopsy of cancer. *Clinical chemistry.*;59(1):110-8.
7. Palmirotta R, Lovero D, Cafforio P, Felici C, Mannavola F, et al (2018). Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. *Ther. Adv. Med. Oncol.*10:1758835918794630.
8. Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, et al (2019). How liquid biopsies can change clinical practice in oncology. *Ann. Oncol.* 30(10):1580-90.
9. Kelley SO, Pantel K (2020). A new era in liquid biopsy: from genotype to phenotype. *Clin. Chem.* 66(1):89-96.
10. Heitzer E, Ulz P, Geigl JB (2015). Circulating tumor DNA as a liquid biopsy for cancer. *Clin. Chem.* 61(1):112-23.